Here is an excerpt from the article about Buffett's involvement in the Yahoo sale: It is being bandied about in the media that billionaire Warren Buffett is backing a consortium which includes Quicken Loans founder Dan Gilbert, a group which is seeking to acquire Yahoo’s assets. The consortium, which is said to be primarily interested in Yahoo! Finance, is one of several bidders who entered the second round of bidding for Yahoo’s core businesses.
You are wrong. With the inherent potential of a blockbuster drug, not even hitting the markets, yet, how can you be so unenlightened to make such an ignorant comment. We can only imagine the intrinsic value of Acadia. Let us know if you feel the same way in a year.
I have read hundreds of articles about Yahoo and I don't think that Couric was ever mentioned. Seems like a big waste of money - but isn't that what Yahoo has been doing for the last ten years?
Hi Paid - I unlocked my "ignore" on you, just to see if you might have come up with an intelligent thought. That was a waste of time. Thank goodness for the "ignore" option.
As a longtime investor in Acadia, even at this point in time, I have realized a significant profit. Still, I find it difficult to understand why the stock price hasn't skyrocketed, after Nuplazid's final approval. It's understandable that upcoming sales will appreciably influence value but just the fact that approval indicates realized potential should create stock appreciation. I'm not sure that I buy the idea that the potential was already reflected in stock price at time of approval. I am still long and will wait for blockbuster sales or a buyout.
I agree that ACAD is in a great position to be bought out. Nuplazid is the only drug for the treatment of PDP that works without any major drawbacks. Ability, the most well-know drug, has links to heart problems, strokes and many more warnings. Seroquel causes significant weight gain and forms enlarged breasts on young boys. Lexapro and Rispordone also are linked to heart problems and strokes. Nuplazid is the only, proven drug that has only minor side effects (headaches). The market for this drug is worth billions. Big pharma companies will certainly be negotiating, before the demand for Nuplazid skyrockets.
Why would ANYONE take so much of their time to bash a particular stock - unless they were paid to do so? It's pretty despicable to be one who profits or gets obvious satisfaction from attempting to thwart other's attempts to better their lives through legitimate investments.
Adam Feuerstein (The Street) has a very interesting article, today. Here is an excerpt: Acadia owns 100% of Nuplazid. An unencumbered, approved (meaning clinically de-risked) drug is a valuable asset. An unencumbered, approved central nervous system (CNS) drug like Nuplazid is both valuable and relatively rare. A number of Big Pharma companies already selling CNS drugs could find Acadia an attractive and profitable addition. Potential suitors include Japanese drug makers like Takeda and Otsuka, both with a reputation for bidding aggressively for U.S. drug assets.
Finally, there's Acadia's efforts to expand Nuplazid into the treatment of psychosis related to Alzheimer's disease to consider. This a high-risk, high-reward development program with a phase II study underway, results expected in the fourth quarter.
Alzheimer's is a very different disease from Parkinson's, so Nuplazid may not work. Any drug seeking an FDA label for Alzheimer's related psychosis will also have to be extremely safe. The risk of death already tied to Nuplazid (and other antipsychotics) makes it tough to handicap Acadia's chances.
Look at the 5-year graph of Amazon and then tell everyone what a big ponzi scheme this is.
some of us long time investors will have a very different opinion.